Abstract: An assembly for mounting an electronic device, includes: a base, a mounting support for mounting the electronic device, and an arm connecting the base and the mounting support, wherein the arm includes: a front locker configured to be coupled to a joint of the mounting support; a rear locker configured to be coupled to the base; a pusher having a front inclined surface in contact with the front locker and a rear inclined surface in contact with the rear locker; and a housing accommodating the front locker, the rear locker, and the pusher.

Abstract: A display device is described including a display panel for displaying an image and an input sensing unit disposed on the display panel for sensing a user input. The input sensing unit includes: an electrode unit including first electrodes and second electrodes which intersect each other and a control unit for determining the proximity of an object or the shape of the object, based on capacitance change values of the first electrodes and the second electrodes. In a first mode the input sensing unit is driven using a self-capacitance method. The control unit may merge the capacitance change values, and determine the proximity of the object based on the merged value. In a second mode based on mutual capacitance, the control unit may determine the shape of the object.

Abstract: The present invention relates to a novel exosome comprising glucosamine, glucosamine derivatives, or salts thereof. The exosome provided by the present invention has an excellent anti-inflammatory effect, and thus can effectively prevent, ameliorate, or treat various inflammatory diseases. The exosome also has an excellent effect of treating intestinal diseases, improving the skin, treating wounds, or treating hair loss.

Abstract: The present invention relates to a composition containing extracellular vesicles derived from plant juice, wherein the extracellular vesicles have excellent skin condition-improving effects such as skin whitening, moisturizing and wrinkle reducing effects and exhibits an excellent effect of preventing hair loss by promotion of hair growth and regrowth, and the like.

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating cancer, comprising, as an active ingredient, miRNA comprising a seed sequence represented by the nucleotide sequence of any one of SEQ ID NOs: 1 to 3; an expression vector comprising the miRNA; or a transformant transformed with the expression vector. The miRNA provided by the present invention can effectively inhibit growth of cancer cells as well as cancer stem cells so that cancer is prevented and/or treated; and, furthermore, the miRNA can also prevent drug resistance, metastasis, and recurrence of cancer.

Abstract: The present invention relates to various uses of a composition comprising plant-derived extracellular vesicles.

Abstract: The present invention provides a method for ameliorating or treating inflammatory bowel disease (IBD) and/or irritable bowel syndrome (IBS), comprising administering extracellular vesicles derived from Kefir grains in a mammal in need thereof. The present invention also provides a pharmaceutical composition for ameliorating or treating IBD and/or IBS or a functional food composition for ameliorating or improving IBD and/or IBS, comprising said extracellular vesicles derived from Kefir grains as an active ingredient.

Abstract: The present invention relates to a composition containing extracellular vesicles derived from plant juice, wherein the extracellular vesicles have excellent skin condition-improving effects such as skin whitening, moisturizing and wrinkle reducing effects and exhibits an excellent effect of preventing hair loss by promotion of hair growth and regrowth, and the like.

Abstract: Disclosed is an anti-obesity active extract obtained from a medicinal plant. More specifically, the extract obtained from lysimachiae foenum-graeci herba (which is a medicinal plant traditionally used in the East) can be used as an active ingredient for a raw material, a functional food, cosmetic, a crude drug, etc. for an obesity preventing or therapeutic agent because the extract can suppress the adipocyte differentiation and decrease the body weight and body fat in an obese animal, thereby suppressing fat accumulation (that is, a factor for obesity).

Abstract: Disclosed are raw material, functional foods, and herb medicines for preventing and treating metabolic diseases, which comprise a Lysimachiae Foenum-Graeci Herba extract as an effective ingredient. The Lysimachiae Foenum-Graeci Herba extract have an activity of reducing blood glucose levels, triglycerides and cholesterol levels, AST and ALT levels, and fat in the liver, and thus can be effectively used as a hepatic protector and a remedy for preventing and treating various metabolic diseases including diabetes, high blood pressure, fatty liver, cardiovascular diseases, and hyperlipidemia.

Abstract: Disclosed is an anti-obesity active extract obtained from a medicinal plant. More specifically, the extract obtained from lysimachiae foenum-graeci herba (which is a medicinal plant traditionally used in the East) can be used as an active ingredient for a raw material, a functional food, cosmetic, a crude drug, etc. for an obesity preventing or therapeutic agent because the extract can suppress the adipocyte differentiation and decrease the body weight and body fat in an obese animal, thereby suppressing fat accumulation (that is, a factor for obesity).

Abstract: Disclosed are mutated genes for green fluorescence proteins and enhanced inserted YFPs expressed therefrom. The mutant proteins not only maintain their fluorescence even at 37° C., but also exhibit about 20 times stronger fluorescence intensities in comparison to the conventional fluorescence proteins. Accordingly, the mutant fluorescence proteins of the present invention can be used as biosensors for detecting and analyzing the bioactivities of desired materials.

Abstract: Disclosed are the methods for producing recombinant viruses using site-specific recombination in vitro. In the present invention, circular viral genomic DNAs are digested with restriction enzymes to generate a linear form viral genomic DNAs flanked by site-specific recombination sites, and then are subjected to site-specific recombination with the desired genomic materials flanked by site-specific recombination sites in vitro. According to the present invention, since the site-specific recombination mixture can be applied to host cells without further procedures of selecting the desired recombinant viral genomic DNAs, it is possible to obtain numerous recombinant viruses rapidly at the same time. Thus, the present invention can be used as a high throughput system for generating and screening hundreds or thousands of recombinant viruses.

Abstract: Disclosed are mutated genes for green fluorescence proteins and enhanced inserted YFPs expressed therefrom. The mutant proteins not only maintain their fluorescence even at 37° C., but also exhibit about 20 times stronger fluorescence intensities in comparison to the conventional fluorescence proteins. Accordingly, the mutant fluorescence proteins of the present invention can be used as biosensors for detecting and analyzing the bioactivities of desired materials.

Abstract: Disclosed are the methods for producing recombinant viruses using site-specific recombination in vitro. In the present invention, circular viral genomic DNAs are digested with restriction enzymes to generate a linear form viral genomic DNAs flanked by site-specific recombination sites, and then are subjected to site-specific recombination with the desired genomic materials flanked by site-specific recombination sites in vitro. According to the present invention, since the site-specific recombination mixture can be applied to host cells without further procedures of selecting the desired recombinant viral genomic DNAs, it is possible to obtain numerous recombinant viruses rapidly at the same time. Thus, the present invention can be used as a high throughput system for generating and screening hundreds or thousands of recombinant viruses.

Abstract: Disclosed are the methods for producing recombinant viruses using in vitro site-specific recombination. In the present invention, linear viral genomic DNAs are digested to two segments, and are subjected to in vitro site-specific recombination with desired genomic materials flanked with site-specific recombinase sites. According to the present invention, since the site-specific recombination mixture can be applied to host cells without further procedures of selecting the recombinant viral genomic DNAs, it is possible to obtain numerous recombinant viruses rapidly at the same time. Thus, the present invention can be used as a high throughput system to generate hundreds or thousands of recombinant viruses.